Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
17.7
39.48
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Arrowhead Pharmaceuticals Inc
Wall Street
Price Targets
ARWR Price Targets Summary
Arrowhead Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
ARWR
is 48.231 USD
with a low forecast of 20.2 USD and a high forecast of 74.55 USD.
ARWR Last Price Targets
Arrowhead Pharmaceuticals Inc
The latest public price target was made on Sep 3, 2024 by
David Lebowitz
from
Citigroup
,
who expects
ARWR
stock to
rise by 45%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
David Lebowitz
Citigroup
|
27
USD
Upside 45% |
2 months ago
Sep 3, 2024
|
Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
StreetInsider
|
|
Patrick Trucchio
H.C. Wainwright
|
60
USD
Upside 223% |
4 months ago
Jul 5, 2024
|
Arrowhead Pharma (ARWR) PT Lowered to $60 at H.C. Wainwright
StreetInsider
|
Andrea Tan
Goldman Sachs
|
31
USD
Upside 67% |
5 months ago
Jun 5, 2024
|
Goldman Sachs Starts Arrowhead Pharma (ARWR) at Neutral
StreetInsider
|
Luca Issi
RBC Capital
|
50
USD
Upside 169% |
5 months ago
May 30, 2024
|
RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR)
StreetInsider
|
|
Unknown Analyst
RBC Capital
|
77
USD
Upside 315% |
1 year ago
Feb 7, 2023
|
RBC Capital Maintains Outperform on Arrowhead Pharma, Lowers Price Target to $77
Benzinga
|
Unknown Analyst
Piper Sandler
|
52
USD
Upside 180% |
1 year ago
Feb 7, 2023
|
Piper Sandler Maintains Overweight on Arrowhead Pharma, Lowers Price Target to $52
Benzinga
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ARWR's stock price target?
Price Target
48.231
USD
According to Wall Street analysts, the average 1-year price target for
ARWR
is 48.231 USD
with a low forecast of 20.2 USD and a high forecast of 74.55 USD.
What is Arrowhead Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
18%
For the last 8 years the
compound annual growth rate for
Arrowhead Pharmaceuticals Inc's revenue is
123%.
The projected
CAGR
for the next 4 years is
18%.
You don't have any saved screeners yet
